| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:1729.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
From the Cardiovascular Surgery (G.M., T.S., H.K.) and Pediatric Cardiology (S.M.-T.), The Heart Institute of Japan, Tokyo Womens Medical University, Shinjuku-ku, Tokyo, Japan; and Suzuka University of Medical Science (Y.I.), Suzuka, Mie, Japan.
Correspondence to Goki Matsumura, MD, Cardiovascular Surgery, The Heart Institute of Japan, Tokyo Womens Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666 Japan. E-mail smatumur{at}hij.twmu.ac.jp
Received May 7, 2003; de novo received July 14, 2003; revision received August 8, 2003; accepted August 8, 2003.
Background Materials commonly used to repair complex cardiac defects lack growth potential and have other unwanted side effects. We designed and tested a bone marrow cell (BMC)seeded biodegradable scaffold that avoids these problems.
Methods and Results To demonstrate the contribution of the BMCs to histogenesis, we labeled them with green fluorescence, seeded them onto scaffolds, and implanted them in the inferior vena cava of dogs. The implanted grafts were analyzed immunohistochemically at 3 hours and subsequently at 2, 4, and 8 weeks after implantation using antibodies against endothelial cell lineage markers, endothelium, and smooth muscle cells. There was no stenosis or obstruction caused by the tissue-engineered vascular autografts (TEVAs) implanted into the dogs. Immunohistochemically, the seeded BMCs expressing endothelial cell lineage markers, such as CD34, CD31, Flk-1, and Tie-2, adhered to the scaffold. This was followed by proliferation and differentiation, resulting in expression of endothelial cells markers, such as CD146, factor VIII, and CD31, and smooth muscle cell markers, such as
-smooth muscle cell actin, SMemb, SM1, and SM2. Vascular endothelial growth factor and angiopoietin-1 were also produced by cells in TEVAs.
Conclusions These results provide direct evidence that the use of BMCs enables the establishment of TEVAs. These TEVAs are useful for cardiovascular surgery in humans and especially in children, who require biocompatible materials with growth potential, which might reduce the instance of complications caused by incompatible materials and lead to a reduced likelihood of further surgery.
Key Words: tissue engineering cells polymers surgery
This article has been cited by other articles:
![]() |
L. Rodriguez-Menocal, M. St-Pierre, Y. Wei, S. Khan, D. Mateu, M. Calfa, A. A. Rahnemai-Azar, G. Striker, S. M. Pham, and R. I. Vazquez-Padron The origin of post-injury neointimal cells in the rat balloon injury model Cardiovasc Res, January 1, 2009; 81(1): 46 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. N. Nelson, J. D. Roh, T. L. Mirensky, Y. Wang, T. Yi, G. Tellides, J. S. Pober, P. Shkarin, E. M. Shapiro, W. M. Saltzman, et al. Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo FASEB J, November 1, 2008; 22(11): 3888 - 3895. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iwasaki, K. Kojima, S. Kodama, A. C. Paz, M. Chambers, M. Umezu, and C. A. Vacanti Bioengineered Three-Layered Robust and Elastic Artery Using Hemodynamically-Equivalent Pulsatile Bioreactor Circulation, September 30, 2008; 118(14_suppl_1): S52 - S57. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Mettler, V. L. Sales, C. L. Stucken, V. Anttila, K. Mendelson, J. Bischoff, and J. E. Mayer Jr Stem Cell-Derived, Tissue-Engineered Pulmonary Artery Augmentation Patches In Vivo Ann. Thorac. Surg., July 1, 2008; 86(1): 132 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Gong and L. E. Niklason Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs) FASEB J, June 1, 2008; 22(6): 1635 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Mayer Tissue Engineering for Cardiac Valve Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 1649 - 1656. [Full Text] |
||||
![]() |
K. Hayashida, K. Kanda, H. Yaku, J. Ando, and Y. Nakayama Development of an in vivo tissue-engineered, autologous heart valve (the biovalve): Preparation of a prototype model J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 152 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Patel, B. Fine, M. Sandig, and K. Mequanint Elastin biosynthesis: The missing link in tissue-engineered blood vessels Cardiovasc Res, July 1, 2006; 71(1): 40 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Isenberg, C. Williams, and R. T. Tranquillo Small-Diameter Artificial Arteries Engineered In Vitro Circ. Res., January 6, 2006; 98(1): 25 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Iwai, Y. Sawa, S. Taketani, K. Torikai, K. Hirakawa, and H. Matsuda Novel Tissue-Engineered Biodegradable Material for Reconstruction of Vascular Wall Ann. Thorac. Surg., November 1, 2005; 80(5): 1821 - 1827. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Ishii, M. Shin, T. Sueda, and J. P. Vacanti In vitro tissue engineering of a cardiac graft using a degradable scaffold with an extracellular matrix-like topography J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1358 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shin'oka, G. Matsumura, N. Hibino, Y. Naito, M. Watanabe, T. Konuma, T. Sakamoto, M. Nagatsu, and H. Kurosawa Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1330 - 1338. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hibino, T. Shin'oka, G. Matsumura, Y. Ikada, and H. Kurosawa The tissue-engineered vascular graft using bone marrow without culture J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1064 - 1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abedin, Y. Tintut, and L. L. Demer Mesenchymal Stem Cells and the Artery Wall Circ. Res., October 1, 2004; 95(7): 671 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Koh and A. Atala Tissue Engineering, Stem Cells, and Cloning: Opportunities for Regenerative Medicine J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1113 - 1125. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |